Clinical Trials Logo

Clinical Trial Summary

This is an exploratory, translational and non-interventional clinical study. The aim of this study is to identify a blood biomarker signature for glioma.


Clinical Trial Description

The identification of biomarkers (proteins, peptides and micro RNAs (miRNAs)) in the serum of patients with glioma would be a new, less invasive approach, which could help in the diagnosis of a glioma, and potentially help guide therapeutic decisions. The investigators will investigate the existence of biomarker profiles, which can - distinguish between low and high grade gliomas - correlate with patient outcomes including response to treatment and survival - indicate progression from a low to a high grade glioma. In this study the investigators collect and analyse blood samples taken from patients with suspected newly diagnosed grade II/III glioma or glioblastoma multiforme (GBM). Blood samples will be collected before any surgical intervention (resection or biopsy) and at various follow-up time points until progression or death. Based on the known natural history of gliomas (described above), it is planned to follow patients with grade III/IV tumours, who receive treatment, for up to 3 years and those with grade II-III tumours, (irrespective of treatment) for up to 5 years. Ultimately, the investigators envisage the translation of our observations into the hospital setting to aid the distinction between glioma grade II and grade III/IV. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03698201
Study type Observational
Source Cancer Trials Ireland
Contact
Status Terminated
Phase
Start date July 2009
Completion date May 2021

See also
  Status Clinical Trial Phase
Withdrawn NCT03796507 - Early Temozolomide in Patients With High-Grade Gliomas in Rehabilitation Early Phase 1
Withdrawn NCT04406610 - CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients Phase 1/Phase 2
Active, not recruiting NCT03665545 - Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma Phase 1/Phase 2
Active, not recruiting NCT03189420 - Glioma Microenvironment an Exploratory Study
Completed NCT03194906 - Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors Phase 2
Active, not recruiting NCT03739372 - Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma N/A
Completed NCT03779230 - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse Phase 1/Phase 2
Recruiting NCT03728673 - A Study Utilizing Escitalopram in Glioma Patients Phase 2
Active, not recruiting NCT03496181 - Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently
Recruiting NCT03180697 - The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas N/A
Recruiting NCT03949192 - Efficacy of Kangliuwan for Recurrent Grade IV Glioma
Terminated NCT03927274 - Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma Early Phase 1
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Not yet recruiting NCT03763396 - Azoles Targeting Recurrent High Grade Gliomas Early Phase 1
Terminated NCT03436433 - Seizure Prophylaxis in Patients With Glioma or Brain Metastasis Phase 2
Recruiting NCT03750890 - Visual Study of Molecular Genotype in Glioma Evolution
Enrolling by invitation NCT03102112 - Noninvasively Predicting Gene Status of Glioma N/A
Active, not recruiting NCT03935685 - Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ Phase 2
Completed NCT03834740 - A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection Early Phase 1
Recruiting NCT03849430 - Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients